Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges

Immune checkpoint inhibitors (ICIs) are the most notable breakthrough in tumor treatment. ICIs has been widely used in tumor patients, but its wide range of immune-related adverse events (irAEs) should not be ignored. irAEs can be involved in any organ system, including immune-related cardiotoxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Lu, Liu, Demin, Ma, Yanan, Chen, Xuening, Dai, Aihui, Zhao, Sihan, Jin, Xiaoxue, Gu, Guoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468595/
https://www.ncbi.nlm.nih.gov/pubmed/36110551
http://dx.doi.org/10.3389/fphar.2022.962596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468595/
https://www.ncbi.nlm.nih.gov/pubmed/36110551
http://dx.doi.org/10.3389/fphar.2022.962596

Ejemplares similares